Literature DB >> 3042461

Efficient production of native, biologically active human cystatin C by Escherichia coli.

M Abrahamson1, H Dalbøge, I Olafsson, S Carlsen, A Grubb.   

Abstract

A cDNA encoding the mature human cysteine proteinase inhibitor cystatin C was fused to the coding sequence for the Escherichia coli outer membrane protein A signal peptide, and the recombinant gene was expressed in E. coli under the control of the lambda PR promoter, an optimized Shine-Dalgarno sequence and the lambda cI 857 repressor. When induced at 42 degrees C, such cells expressed large amounts of recombinant cystatin C. The recombinant protein was isolated in high yield and characterized. All physicochemical properties investigated, including the positions of disulfide bonds, indicated that the E. coli derived cystatin C was identical to cystatin C isolated from human biological fluids, except that the proline residue in position three was not hydroxylated. The recombinant protein displayed full biological activity against papain, cathepsin B and dipeptidyl peptidase I.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042461     DOI: 10.1016/0014-5793(88)80276-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

1.  Low-level internalization of cystatin E/M affects legumain activity and migration of melanoma cells.

Authors:  Hanna Wallin; Jenny Apelqvist; Freddi Andersson; Ulf Ekström; Magnus Abrahamson
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

2.  Amino acid substitutions in the N-terminal segment of cystatin C create selective protein inhibitors of lysosomal cysteine proteinases.

Authors:  R W Mason; K Sol-Church; M Abrahamson
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  Differential changes in the association and dissociation rate constants for binding of cystatins to target proteinases occurring on N-terminal truncation of the inhibitors indicate that the interaction mechanism varies with different enzymes.

Authors:  I Björk; E Pol; E Raub-Segall; M Abrahamson; A D Rowan; J S Mort
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

4.  Crosstalk of Various Biomarkers That Might Provide Prompt Identification of Acute or Chronic Cardiorenal Syndromes.

Authors:  Danijela Tasić; Sonja Radenkovic; Dijana Stojanovic; Maja Milojkovic; Miodrag Stojanovic; Marina Deljanin Ilic; Gordana Kocic
Journal:  Cardiorenal Med       Date:  2015-11-11       Impact factor: 2.041

5.  Crystallization and preliminary X-ray diffraction analysis of Val57 mutants of the amyloidogenic protein human cystatin C.

Authors:  Marta Orlikowska; Elzbieta Jankowska; Dominika Borek; Zbyszek Otwinowski; Piotr Skowron; Aneta Szymańska
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-26

6.  Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes.

Authors:  Hanna Wallin; Magnus Abrahamson; Ulf Ekström
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

7.  Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells.

Authors:  M Bjarnadottir; B S Wulff; M Sameni; B F Sloane; D Keppler; A Grubb; M Abrahamson
Journal:  Mol Pathol       Date:  1998-12

8.  Increased body temperature accelerates aggregation of the Leu-68-->Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy.

Authors:  M Abrahamson; A Grubb
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Inhibitory effects of recombinant human cystatin C on human coronaviruses.

Authors:  A R Collins; A Grubb
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Importance of the evolutionarily conserved glycine residue in the N-terminal region of human cystatin C (Gly-11) for cysteine endopeptidase inhibition.

Authors:  A Hall; H Dalbøge; A Grubb; M Abrahamson
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.